Using a new drug to help pancreatic cancer respond to immunotherapy
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy
This project gives a drug called GB1275 together with chemotherapy and a PD-1 immunotherapy to people with metastatic pancreatic cancer to boost the immune attack on tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11187264 on NIH RePORTER |
What this research studies
If you join, doctors will give a CD11b-agonist called GB1275 along with standard chemotherapy (gemcitabine and Abraxane) and a PD-1 blocking immunotherapy. They will monitor safety with regular visits, scans, and blood tests to see how tumors respond. The team will collect blood and tumor samples to measure drug exposure and immune changes. Lab analyses will examine tumor and immune features that might explain who benefits or becomes resistant.
Who could benefit from this research
Good fit: Adults with metastatic pancreatic ductal adenocarcinoma who are eligible for gemcitabine/Abraxane and PD-1 therapy and meet safety requirements could be candidates.
Not a fit: People with early-stage pancreatic cancer, those who cannot tolerate chemotherapy or immunotherapy, or those with serious medical problems that prevent trial participation are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this approach could make immunotherapy work for some people with pancreatic cancer, improving tumor control and survival.
How similar studies have performed: Preclinical mouse and laboratory studies showed that CD11b agonists like GB1275 can reprogram suppressive immune cells and, combined with PD-1 blockers, cause tumor regression, but clear benefits in people remain to be shown.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.